Pamidronate ( DrugBank: Pamidronate )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 270 | 慢性再発性多発性骨髄炎 | 1 |
| 271 | 強直性脊椎炎 | 1 |
| 274 | 骨形成不全症 | 8 |
270. 慢性再発性多発性骨髄炎
臨床試験数 : 1 / 薬物数 : 10 - (DrugBank : 9) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 73
Showing 1 to 1 of 1 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04725422 (ClinicalTrials.gov) | August 1, 2018 | 18/1/2021 | CHronic Nonbacterial Osteomyelitis International Registry (CHOIR) | CHronic Nonbacterial Osteomyelitis International Registry (CHOIR) | Chronic Nonbacterial Osteomyelitis;Chronic Recurrent Multifocal Osteomyelitis | Drug: Methotrexate;Drug: Sulfasalazine;Drug: Leflunomide;Drug: Pamidronate;Drug: Zoledronic acid;Drug: Etanercept;Drug: Adalimumab;Drug: Certolizumab;Drug: Infliximab;Drug: Golimumab Drug: Methotrexate;Drug: Sulfasalazine;Drug: Leflunomide;Drug: Pamidronate;Drug: Zoledronic acid;Dru ... | Seattle Children's Hospital | Boston Children's Hospital, Boston, MA, USA;Hospital for Special Surgery, New York City, NY, USA;Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA;Riley Children's Hospital, Indianapolis, IN, USA;University of North Carolina, Chapel Hill, NC, USA;Royal Children's Hospital, Melbourne, Australia;Hacettepe University, Ankara, Turkey;Bambino Gesù Children's Hospital, Rome, Italy;University of British Columbia, Vancouver, BC, Canada;Meyer Children's Hospital, Florence, Italy;Mansoura university, faculty of medicine, Egypt Boston Children's Hospital, Boston, MA, USA;Hospital for Special Surgery, New York City, NY, USA;Jos ... | Recruiting | N/A | 21 Years | All | 2000 | United States |
271. 強直性脊椎炎
臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
Showing 1 to 1 of 1 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02313727 (ClinicalTrials.gov) | December 2014 | 1/12/2014 | Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Combined Treatment With TNF Inhibitor and Pamidronatein AS Patients: Effect on the Radiographic Prog ... | Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronatein AS Patients: Effect ... | Ankylosing Spondylitis | Drug: Pamidronate;Other: Placebo (NaCl 0.9%) | Bnai Zion Medical Center | Janssen-Cilag Ltd. | Not yet recruiting | 18 Years | N/A | Male | 30 | Phase 4 | Israel |
274. 骨形成不全症
臨床試験数 : 91 / 薬物数 : 101 - (DrugBank : 20) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 48
Showing 1 to 8 of 8 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-003228-22-NL (EUCTR) | 13/01/2021 | 27/11/2020 | Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid | Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study | Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenes ... | Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Bonefos Product Name: Bonefos Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledroni ... | University of Edinburgh | NHS Lothian | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 380 | Phase 4 | Ireland;Netherlands;United Kingdom | ||
| 2 | JPRN-UMIN000031290 | 2018/05/30 | 01/04/2018 | Efficacy of pamidronate for adult osteogenesis imperfecta: uncontrolled study. | Efficacy of pamidronate for adult osteogenesis imperfecta: uncontrolled study. - Efficacy of pamidronate for adult osteogenesis imperfecta Efficacy of pamidronatefor adult osteogenesis imperfecta: uncontrolled study. - Efficacy of pamidron ... | Osteogenesis imperfecta | Pamidronate disodium intervenous for drip use; 15mg/day (available up to 30mg/day), 1 infection/day x 3 dats, every 4 months, total 16 months. Pamidronatedisodium intervenous for drip use; 15mg/day (available up to 30mg/day), 1 infection/day x ... | Kobe University Hospital | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 10 | Not applicable | Japan |
| 3 | EUCTR2016-003228-22-IE (EUCTR) | 22/06/2017 | 03/11/2016 | Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid | Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study | Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenes ... | Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Clasteon Product Name: Clasteon Trade Name: Calcichew D3 Product Name: Calcichew D3 Trade Name: Fultium-D3 800IU capsules Product Name: Fultium-D3 800IU capsules Trade Name: Prolia Product Name: Prolia Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledroni ... | University of Edinburgh | NHS Lothian | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 380 | Phase 4 | Ireland;Netherlands;United Kingdom | ||
| 4 | EUCTR2016-003228-22-GB (EUCTR) | 14/12/2016 | 19/10/2016 | Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid | Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study | Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11] Osteogenesis imperfecta MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenes ... | Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledronic acid Trade Name: Alendronic acid Product Name: Alendronic acid Trade Name: Risedronate sodium Product Name: Risedronate sodium Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Ibandronic acid Product Name: Ibandronic acid Trade Name: Disodium Pamidronate 15mg (15mg strength) Product Name: Disodium Pamidronate 15mg (15mg strength) Trade Name: Prolia Product Name: Prolia Trade Name: Bonefos Product Name: Bonefos Trade Name: Teriparatide Product Name: Teriparatide Trade Name: Zoledronic acid Product Name: Zoledroni ... | University of Edinburgh | NHS Lothian | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 380 | Phase 4 | Netherlands;Ireland;Denmark;United Kingdom | ||
| 5 | NCT00655681 (ClinicalTrials.gov) | September 2007 | 4/4/2008 | Prevention of Post Operative Bone Loss in Children | Prevention of Post Operative Bone Loss in Children | Osteoporosis;Cerebral Palsy;Spina Bifida;Osteopenia;Osteogenesis Imperfecta | Drug: pamidronate;Other: saline | University of New Mexico | Thrasher Research Fund | Completed | 4 Years | 18 Years | Both | 24 | N/A | United States |
| 6 | NCT00005901 (ClinicalTrials.gov) | June 2000 | 6/6/2000 | Pamidronate to Treat Osteogenesis Imperfecta in Children | A Trial of Pamidronate in Children With Osteogenesis Imperfecta | Osteogenesis Imperfecta | Drug: Pamidronate (Aredia) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | National Institutes of Health Clinical Center (CC) | Completed | N/A | 16 Years | All | 34 | Phase 3 | United States;Canada |
| 7 | NCT00159419 (ClinicalTrials.gov) | August 1999 | 7/9/2005 | Bisphosphonate Therapy for Osteogenesis Imperfecta | Bisphosphonate Therapy for Osteogenesis Imperfecta | Osteogenesis Imperfecta;Osteoporosis;Paget Disease of Bone | Drug: Alendronate;Drug: Pamidronate | Indiana University School of Medicine | NULL | Completed | 3 Years | 21 Years | All | 18 | Phase 4 | United States |
| 8 | EUCTR2015-003539-37-Outside-EU/EEA (EUCTR) | 07/03/2016 | Bisphosphonate Treatment of Osteogenesis Imperfecta | An international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imperfect. An international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intrav ... | Osteogenesis Imperfecta;Therapeutic area: Diseases [C] - Cancer [C04] | Trade Name: Zometa | Novartis | NULL | NA | Female: yes Male: yes | 158 | United States |